At first glance, the reported sales for Biogen, Inc./Eisai Co., Ltd.’s newly launched Alzheimer’s treatment Aduhelm (aducanumab) looks like a typo: $300,000 in the third quarter.
That, after all, is at least nine zeros short of the theoretical market size for the therapy at the time...